The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Natural Killer Cell (CYNK-001) Infusions in Adults With AML
Official Title: A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) With or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults With Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission With Minimal Residual Disease (MRD) or Relapsed/Refractory (R/R) AML
Study ID: NCT04310592
Brief Summary: This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating acute myeloid leukemia.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Colorado Blood Cancer Institute, Denver, Colorado, United States
University of Chicago, Chicago, Illinois, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Columbia University and New York Presbyterian Hospital, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Westchester Medical Center, Valhalla, New York, United States
Tennessee Oncology, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
Swedish Health Services, Seattle, Washington, United States
Name: Cherie Daly, MD
Affiliation: Celularity, Inc.
Role: STUDY_DIRECTOR